According to the European Society of Atherosclerosis (EAS), screening for elevated Lp(a) should be performed in subjects at high cardiovascular risk with premature coronary artery disease, familial hypercholesterolemia, in patients with a family history of coronary artery disease, and in those with recurrent coronary artery disease despite lipid-lowering therapy, which includes a large proportion of patients with diabetes [3]. This evidence concerns the gene LPA and coronary artery disorder.